US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
KR0154880B1
(ko)
*
|
1992-06-15 |
1998-10-15 |
피터 알.셰어러 |
글루카곤-유사 펩티드 및 인슐리노트로핀 유도체
|
US6558952B1
(en)
*
|
1992-12-14 |
2003-05-06 |
Waratah Pharmaceuticals, Inc. |
Treatment for diabetes
|
US6284727B1
(en)
*
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
GB9409496D0
(en)
*
|
1994-05-12 |
1994-06-29 |
London Health Ass |
Method for improving glycaemic control in diabetes
|
US5574008A
(en)
*
|
1994-08-30 |
1996-11-12 |
Eli Lilly And Company |
Biologically active fragments of glucagon-like insulinotropic peptide
|
US5512549A
(en)
*
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
US5834428A
(en)
*
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
PT1975177E
(pt)
*
|
1996-03-01 |
2011-07-26 |
Novo Nordisk As |
Peptídeo supressor do apetite, sua composição e uso
|
US5912229A
(en)
*
|
1996-03-01 |
1999-06-15 |
Novo Nordisk Als |
Use of a pharmaceutical composition comprising an appetite-suppressing peptide
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
DK1629849T4
(da)
|
1997-01-07 |
2017-12-04 |
Amylin Pharmaceuticals Llc |
Farmaceutiske sammensætninger omfattende exediner og agonister deraf
|
US5981488A
(en)
*
|
1997-03-31 |
1999-11-09 |
Eli Lillly And Company |
Glucagon-like peptide-1 analogs
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
ES2222613T3
(es)
*
|
1997-09-12 |
2005-02-01 |
Pharis Biotec Gmbh |
Composicion para la terapia de diabetes mellitus y de la obesidad.
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
EP1066314B1
(en)
|
1997-11-14 |
2007-12-26 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
EP2574336A1
(en)
*
|
1998-02-02 |
2013-04-03 |
Trustees Of Tufts College |
Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
|
EP1840134B1
(en)
|
1998-02-27 |
2016-04-13 |
Novo Nordisk A/S |
GLP-1 derivatives
|
ATE466028T1
(de)
*
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
N-terminal veränderte glp-1 abkömmlinge
|
ATE466027T1
(de)
*
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
Abkömmlinge von glp-1 analogen
|
AU3247799A
(en)
*
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
JP2002508162A
(ja)
*
|
1998-02-27 |
2002-03-19 |
ノボ ノルディスク アクティーゼルスカブ |
N末端を短縮したglp−1誘導体
|
NZ506202A
(en)
|
1998-03-19 |
2003-10-31 |
Bristol Myers Squibb Co |
Biphasic controlled release delivery system for high solubility pharmaceuticals and method
|
AU3087599A
(en)
*
|
1998-03-19 |
1999-10-11 |
Bionebraska, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
US6099859A
(en)
*
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
EP0974356B1
(en)
*
|
1998-07-15 |
2003-09-24 |
Merck Sante |
Tablets comprising a combination of metformin and glibenclamide
|
US20040037818A1
(en)
*
|
1998-07-30 |
2004-02-26 |
Brand Stephen J. |
Treatment for diabetes
|
US6099862A
(en)
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
EP1652531A1
(en)
*
|
1998-09-24 |
2006-05-03 |
Eli Lilly & Company |
Use of GLP-1 or Analogues in Treatment of Stroke
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
ATE394423T1
(de)
*
|
1998-12-07 |
2008-05-15 |
Sod Conseils Rech Applic |
Analoge des glucagon ähnlichen peptides-1 (glp-1)
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
EP1849475A1
(en)
|
1999-06-21 |
2007-10-31 |
Eli Lilly & Company |
Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
DK2280021T3
(da)
|
1999-06-29 |
2016-05-02 |
Mannkind Corp |
Farmaceutiske formuleringer omfattende insulin kompleksbundet til et diketopiperazin
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US20060160740A1
(en)
*
|
1999-10-21 |
2006-07-20 |
Suad Efendic |
Use of GLP-1 or analogs in treatment of stroke
|
US6586438B2
(en)
*
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
EP1229918B1
(en)
|
1999-11-03 |
2008-03-26 |
Bristol-Myers Squibb Company |
Pharmaceutical composition comprising a combination of metformin and glibenclamide
|
US7229793B1
(en)
*
|
1999-11-19 |
2007-06-12 |
Shire Human Genetic Therapies, Inc. |
Constructs and cells for production of small peptides
|
US20010036479A1
(en)
*
|
2000-01-14 |
2001-11-01 |
Gillian Cave |
Glyburide composition
|
EP1263458B1
(en)
*
|
2000-03-08 |
2005-11-16 |
Novo Nordisk A/S |
Lowering serum cholesterol
|
US20030040469A1
(en)
*
|
2000-03-08 |
2003-02-27 |
Knudsen Liselotte Bjerre |
Lowering serum lipids
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
HU229042B1
(en)
*
|
2000-03-31 |
2013-07-29 |
Prosidion Ltd |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
CA2405563A1
(en)
*
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20060034922A1
(en)
*
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US6790459B1
(en)
|
2000-11-03 |
2004-09-14 |
Andrx Labs, Llc |
Methods for treating diabetes via administration of controlled release metformin
|
US6866866B1
(en)
*
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US7199217B2
(en)
|
2000-12-13 |
2007-04-03 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
MXPA03007358A
(es)
*
|
2001-02-16 |
2004-12-13 |
Cellgate Inc |
Transportadores que contienen porciones de arginina separadas.
|
DE60209343T2
(de)
|
2001-04-11 |
2006-10-26 |
Bristol-Myers Squibb Co. |
Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
|
EP1401477A4
(en)
*
|
2001-05-25 |
2005-02-02 |
Human Genome Sciences |
CHIMIOKINE BETA-1 HYBRID PROTEINS
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
MXPA04003569A
(es)
*
|
2001-10-19 |
2004-07-23 |
Lilly Co Eli |
Mezclas bifasicas de glp-1 e insulina.
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
EP1443919A4
(en)
*
|
2001-11-16 |
2006-03-22 |
Bristol Myers Squibb Co |
DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
|
CA2468192A1
(en)
|
2001-11-26 |
2003-06-05 |
Trustees Of Tufts College |
Peptidomimetic inhibitors of post-proline cleaving enzymes
|
AU2002360453C1
(en)
*
|
2001-11-26 |
2009-06-18 |
The Brigham And Women's Hospital, Inc. |
Methods for treating autoimmune disorders, and reagents related thereto
|
ES2500918T3
(es)
|
2001-12-21 |
2014-10-01 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina e interferón beta
|
US20050148497A1
(en)
*
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
CA2479751C
(en)
|
2002-03-20 |
2008-06-03 |
Trent Poole |
Inhalation apparatus
|
JP4478563B2
(ja)
*
|
2002-05-14 |
2010-06-09 |
プレゼント インヴェストメンツ エルエルシー |
送信信号の形成方法
|
AU2003241537A1
(en)
*
|
2002-05-23 |
2003-12-12 |
Andrx Corporation |
Biguanide formulations
|
US20060234373A1
(en)
*
|
2002-05-24 |
2006-10-19 |
Alex Rabinovitch |
Treatment for diabetes
|
EP1511509B1
(en)
|
2002-06-07 |
2007-10-10 |
Waratah Pharmaceuticals, Inc. |
Compositions and methods for treating diabetes
|
ATE432289T1
(de)
*
|
2002-07-04 |
2009-06-15 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
AU2003268621B2
(en)
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
JP2006506386A
(ja)
*
|
2002-10-22 |
2006-02-23 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
糖尿病の処置
|
ES2344057T3
(es)
*
|
2002-10-23 |
2010-08-17 |
Bristol-Myers Squibb Company |
Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
|
US20040176425A1
(en)
*
|
2003-01-24 |
2004-09-09 |
Washburn William N. |
Cycloalkyl containing anilide ligands for the thyroid receptor
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
EP1743676A1
(en)
*
|
2003-11-12 |
2007-01-17 |
Phenomix Corporation |
Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US20060286129A1
(en)
*
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
BRPI0507189A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Waratah Pharmaceuticals Inc |
uso combinado de um agonista de glp-1 e compostos de gastrina
|
JP2008505975A
(ja)
*
|
2004-07-12 |
2008-02-28 |
フェノミックス コーポレーション |
制約されたシアノ化合物
|
BRPI0514263B8
(pt)
|
2004-08-20 |
2021-05-25 |
Mannkind Corp |
método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
|
DK2314298T3
(da)
|
2004-08-23 |
2015-06-15 |
Mannkind Corp |
Mikropartikler omfattende diketopiperazinsalte til lægemiddel-afgivelse
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
EP1858545A2
(en)
*
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
JP2008545712A
(ja)
|
2005-05-25 |
2008-12-18 |
キュアーディーエム、インク. |
ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
US7803404B2
(en)
|
2005-09-14 |
2010-09-28 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
|
EP1943215A2
(en)
|
2005-10-31 |
2008-07-16 |
Brystol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
BRPI0707991B8
(pt)
|
2006-02-22 |
2021-05-25 |
Mannkind Corp |
métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
EP2089389A2
(en)
|
2006-11-01 |
2009-08-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
|
EP2089355A2
(en)
|
2006-11-01 |
2009-08-19 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
|
US8198311B2
(en)
|
2006-11-01 |
2012-06-12 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2008064306A2
(en)
*
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
KR100860561B1
(ko)
*
|
2007-05-02 |
2008-09-26 |
경희대학교 산학협력단 |
컴파운드 k 및 메트포민을 유효성분으로 포함하는당뇨병의 예방 및 치료용 약학적 조성물
|
NZ599755A
(en)
*
|
2007-08-30 |
2013-08-30 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
CN101969928B
(zh)
*
|
2007-10-24 |
2014-05-07 |
曼金德公司 |
活性剂的递送
|
AU2008316634B2
(en)
*
|
2007-10-24 |
2014-02-27 |
Mannkind Corporation |
Method of preventing adverse effects by GLP-1
|
WO2009058944A2
(en)
|
2007-11-01 |
2009-05-07 |
Bristol-Myers Squibb Company |
Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
|
US9358352B2
(en)
|
2008-06-13 |
2016-06-07 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
AU2009257311B2
(en)
|
2008-06-13 |
2014-12-04 |
Mannkind Corporation |
A dry powder inhaler and system for drug delivery
|
DK2300083T3
(da)
|
2008-06-20 |
2013-07-22 |
Mannkind Corp |
Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg
|
US8106046B2
(en)
|
2008-06-24 |
2012-01-31 |
Bristol-Myers Squibb Company |
Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
TWI494123B
(zh)
|
2008-08-11 |
2015-08-01 |
Mannkind Corp |
超快起作用胰島素之用途
|
GB0817969D0
(en)
*
|
2008-10-01 |
2008-11-05 |
Axcess Ltd |
Pharmaceutical composition
|
RS56632B1
(sr)
|
2008-10-17 |
2018-03-30 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
US8538707B2
(en)
|
2009-03-11 |
2013-09-17 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
US8790916B2
(en)
*
|
2009-05-14 |
2014-07-29 |
Genestream, Inc. |
Microfluidic method and system for isolating particles from biological fluid
|
KR101875969B1
(ko)
|
2009-06-12 |
2018-07-06 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
WO2011056889A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
ES2855146T3
(es)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
CN102770152B
(zh)
|
2009-11-25 |
2016-07-06 |
阿瑞斯根股份有限公司 |
肽类的粘膜递送
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
JP5969461B2
(ja)
|
2010-04-27 |
2016-08-17 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
|
CN103153288B
(zh)
|
2010-07-09 |
2017-02-15 |
詹姆斯·特林卡·格林 |
用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
|
HUE031181T2
(en)
|
2010-08-30 |
2017-06-28 |
Sanofi Aventis Deutschland |
Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
|
CN102643339B
(zh)
*
|
2011-02-21 |
2014-04-09 |
天津药物研究院 |
一种glp-1类似物、制备方法及其应用
|
ES2625858T3
(es)
|
2011-04-01 |
2017-07-20 |
Mannkind Corporation |
Paquete de tipo blíster para cartuchos farmacéuticos
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
EP2526971A1
(en)
|
2011-05-25 |
2012-11-28 |
ArisGen SA |
Mucosal delivery of drugs
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
JP6018640B2
(ja)
|
2011-10-24 |
2016-11-02 |
マンカインド コーポレイション |
疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
|
CA2853884A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
ES2624294T3
(es)
|
2012-07-12 |
2017-07-13 |
Mannkind Corporation |
Sistemas de suministro de fármacos en polvo seco
|
WO2014016300A1
(en)
|
2012-07-23 |
2014-01-30 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
EP2970149B1
(en)
|
2013-03-15 |
2019-08-21 |
MannKind Corporation |
Microcrystalline diketopiperazine compositions and methods
|
CN114848614A
(zh)
|
2013-07-18 |
2022-08-05 |
曼金德公司 |
热稳定性干粉药物组合物和方法
|
CA2920488C
(en)
|
2013-08-05 |
2022-04-26 |
Mannkind Corporation |
Insufflation apparatus and methods
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
BR112016008115B1
(pt)
|
2013-10-17 |
2024-03-12 |
Boehringer Ingelheim International Gmbh |
Análogos de glucagon acilados
|
BR112016009995B1
(pt)
|
2013-11-06 |
2023-04-18 |
Zealand Pharma A/S |
Compostos agonistas triplos glucagon-glp-1-gip
|
WO2015067715A2
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
US9839692B2
(en)
|
2014-01-09 |
2017-12-12 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
BR112016013832A2
(pt)
|
2014-01-09 |
2017-08-08 |
Sanofi Sa |
Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
|
EP3091964A1
(en)
|
2014-01-09 |
2016-11-16 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
WO2015148905A1
(en)
|
2014-03-28 |
2015-10-01 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
JP6898231B6
(ja)
|
2014-10-29 |
2021-07-28 |
ジーランド ファーマ アクティーゼルスカブ |
Gipアゴニスト化合物及び方法
|
JP6970615B2
(ja)
|
2014-12-12 |
2021-11-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリングラルギン/リキシセナチド固定比処方
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
ES2763329T3
(es)
|
2015-04-16 |
2020-05-28 |
Zealand Pharma As |
Análogo de glucagón acilado
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|